Intravitreal aflibercept for neovascular age-related macular degeneration.
about
Treatment of Exudative Age-related Macular Degeneration: Focus on AfliberceptA safety study of high concentration and high frequency intravitreal injection of conbercept in rabbitsOptical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Ritonavir inhibits HIF-1α-mediated VEGF expression in retinal pigment epithelial cells in vitro.Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
P2860
Intravitreal aflibercept for neovascular age-related macular degeneration.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Intravitreal aflibercept for neovascular age-related macular degeneration.
@en
Intravitreal aflibercept for neovascular age-related macular degeneration.
@nl
type
label
Intravitreal aflibercept for neovascular age-related macular degeneration.
@en
Intravitreal aflibercept for neovascular age-related macular degeneration.
@nl
prefLabel
Intravitreal aflibercept for neovascular age-related macular degeneration.
@en
Intravitreal aflibercept for neovascular age-related macular degeneration.
@nl
P2860
P356
P1433
P1476
Intravitreal aflibercept for neovascular age-related macular degeneration
@en
P2093
P2860
P304
P356
10.2217/IMT.12.158
P577
2013-02-01T00:00:00Z